Favipiravir was synthesized from 3-amino-2-pyrazinecarboxylic acid by esterification, bromination with NBS, diazotization and amination to give 6-bromo-3-hydroxypyrazine-2-carboxamide, which was subjected to chlorination with POCl3, fluorination with KF, and hydrolysis with an overall yield of about 22％.
. Synthesis of Favipiravir[J]. CJPH, 2013, 44(9): 841-843.
Furuta Y, Takahashi K, Fukuda Y, et al. In vitro and in vivo activities of anti-influenza virus compound T-705 [ J] .Antimicrob Agents Chemother, 2002, 46(4): 977-981.
Ki s o M, Ta k a h a s h i K, S a k a i - Ta g awa Y, e t a l .T-705(favipiravir) activity against lethal H5N1 influenza A viruses [J]. Proc Natl Acad Sci U S A, 2010, 107(2):882-887.
Gowen BB, Wong MH, Jung KH, et al. In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections [J]. Antimicrob Agents Chemother, 2007, 51(9):3168-3176.
Julander JG, Shafer K, Smee DF, et al. Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106 [J].Antimicrob Agents Chemother, 2009, 53(1): 202-209.
Furuta Y. Nitrogenous heterocyclic carboxamide derivatives or salts thereof and antiviral agents containing both: WO,00/10569 [P]. 2003-03-02.
Forns P, Esteve C, Taboada L, et al. Pyrazine-based Syk kinase inhibitors [J]. Bioorg Med Chem. Lett, 2012, 22(8):2784-2788.
Charrier JD, Durrant SJ, Golec JM, et al. Discovery of potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase as potential anticancer
agents [J]. J Med Chem, 2011, 54(7): 2320-2330.
Caldwell JJ, Veillard N, Collins I. Design and synthesis of 2(1H)-pyrazinones as inhibitors of protein kinases [J].Tetrahedron, 2012, 68(2012): 9713-9728.
Beldar SV, Jordis U. Synthetic studies towards the antiviral pyrazine derivative T-705 [C]// 13th International Electronic Conference on Synthetic Organic Chemistry, 2009.
Tamio H. Method for producing dichloropyrazine derivative:WO, 2010/087117 [P]. 2012-08-05.